nodes	percent_of_prediction	percent_of_DWPC	metapath
Rivaroxaban—CYP3A5—Progesterone—uterine cancer	0.146	0.229	CbGbCtD
Rivaroxaban—ABCB1—Progesterone—uterine cancer	0.0949	0.149	CbGbCtD
Rivaroxaban—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0859	0.135	CbGbCtD
Rivaroxaban—ABCB1—Dactinomycin—uterine cancer	0.0753	0.118	CbGbCtD
Rivaroxaban—CYP3A5—Etoposide—uterine cancer	0.0653	0.102	CbGbCtD
Rivaroxaban—CYP3A4—Progesterone—uterine cancer	0.0569	0.0891	CbGbCtD
Rivaroxaban—ABCB1—Etoposide—uterine cancer	0.0425	0.0666	CbGbCtD
Rivaroxaban—ABCB1—Doxorubicin—uterine cancer	0.029	0.0454	CbGbCtD
Rivaroxaban—CYP3A4—Etoposide—uterine cancer	0.0255	0.0399	CbGbCtD
Rivaroxaban—CYP3A4—Doxorubicin—uterine cancer	0.0174	0.0272	CbGbCtD
Rivaroxaban—CYP2J2—artery—uterine cancer	0.0134	0.149	CbGeAlD
Rivaroxaban—F10—uterine cervix—uterine cancer	0.00616	0.0682	CbGeAlD
Rivaroxaban—F10—decidua—uterine cancer	0.00587	0.0649	CbGeAlD
Rivaroxaban—F10—endometrium—uterine cancer	0.00557	0.0617	CbGeAlD
Rivaroxaban—F10—mammalian vulva—uterine cancer	0.00539	0.0596	CbGeAlD
Rivaroxaban—F10—female reproductive system—uterine cancer	0.00462	0.0511	CbGeAlD
Rivaroxaban—CYP2J2—endometrium—uterine cancer	0.00457	0.0505	CbGeAlD
Rivaroxaban—CYP2J2—mammalian vulva—uterine cancer	0.00442	0.0489	CbGeAlD
Rivaroxaban—CYP2J2—uterus—uterine cancer	0.00421	0.0466	CbGeAlD
Rivaroxaban—F10—female gonad—uterine cancer	0.0042	0.0465	CbGeAlD
Rivaroxaban—F10—vagina—uterine cancer	0.00418	0.0462	CbGeAlD
Rivaroxaban—CYP2J2—female reproductive system—uterine cancer	0.00379	0.0419	CbGeAlD
Rivaroxaban—CYP2J2—vagina—uterine cancer	0.00342	0.0379	CbGeAlD
Rivaroxaban—F10—lymph node—uterine cancer	0.0027	0.0299	CbGeAlD
Rivaroxaban—CYP3A5—uterine cervix—uterine cancer	0.00178	0.0197	CbGeAlD
Rivaroxaban—CYP3A5—renal system—uterine cancer	0.00166	0.0184	CbGeAlD
Rivaroxaban—CYP3A4—renal system—uterine cancer	0.00125	0.0138	CbGeAlD
Rivaroxaban—ABCB1—myometrium—uterine cancer	0.00121	0.0134	CbGeAlD
Rivaroxaban—CYP3A5—female gonad—uterine cancer	0.00121	0.0134	CbGeAlD
Rivaroxaban—CYP3A5—vagina—uterine cancer	0.0012	0.0133	CbGeAlD
Rivaroxaban—CYP3A4—female reproductive system—uterine cancer	0.001	0.0111	CbGeAlD
Rivaroxaban—ABCB1—epithelium—uterine cancer	0.000953	0.0105	CbGeAlD
Rivaroxaban—ABCB1—uterine cervix—uterine cancer	0.000945	0.0104	CbGeAlD
Rivaroxaban—ABCB1—decidua—uterine cancer	0.0009	0.00995	CbGeAlD
Rivaroxaban—ABCB1—renal system—uterine cancer	0.000884	0.00977	CbGeAlD
Rivaroxaban—ABCB1—endometrium—uterine cancer	0.000854	0.00945	CbGeAlD
Rivaroxaban—ABCB1—mammalian vulva—uterine cancer	0.000826	0.00914	CbGeAlD
Rivaroxaban—ABCB1—uterus—uterine cancer	0.000787	0.00871	CbGeAlD
Rivaroxaban—Pain—Progesterone—uterine cancer	0.000738	0.00286	CcSEcCtD
Rivaroxaban—Constipation—Progesterone—uterine cancer	0.000738	0.00286	CcSEcCtD
Rivaroxaban—Blood bilirubin increased—Epirubicin—uterine cancer	0.000734	0.00285	CcSEcCtD
Rivaroxaban—Hypotension—Medroxyprogesterone Acetate—uterine cancer	0.000731	0.00284	CcSEcCtD
Rivaroxaban—Feeling abnormal—Progesterone—uterine cancer	0.000711	0.00276	CcSEcCtD
Rivaroxaban—Rectal haemorrhage—Doxorubicin—uterine cancer	0.000711	0.00276	CcSEcCtD
Rivaroxaban—ABCB1—female reproductive system—uterine cancer	0.000708	0.00783	CbGeAlD
Rivaroxaban—Gastrointestinal pain—Progesterone—uterine cancer	0.000706	0.00274	CcSEcCtD
Rivaroxaban—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.000697	0.00271	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Dactinomycin—uterine cancer	0.000694	0.00269	CcSEcCtD
Rivaroxaban—Infestation NOS—Etoposide—uterine cancer	0.000692	0.00269	CcSEcCtD
Rivaroxaban—Infestation—Etoposide—uterine cancer	0.000692	0.00269	CcSEcCtD
Rivaroxaban—Anaemia—Dactinomycin—uterine cancer	0.000691	0.00268	CcSEcCtD
Rivaroxaban—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.000689	0.00267	CcSEcCtD
Rivaroxaban—Stevens-Johnson syndrome—Etoposide—uterine cancer	0.000687	0.00266	CcSEcCtD
Rivaroxaban—Urticaria—Progesterone—uterine cancer	0.000686	0.00266	CcSEcCtD
Rivaroxaban—Abdominal pain—Progesterone—uterine cancer	0.000682	0.00265	CcSEcCtD
Rivaroxaban—Renal failure—Etoposide—uterine cancer	0.000681	0.00264	CcSEcCtD
Rivaroxaban—Blood bilirubin increased—Doxorubicin—uterine cancer	0.000679	0.00263	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000675	0.00262	CcSEcCtD
Rivaroxaban—Jaundice—Etoposide—uterine cancer	0.000675	0.00262	CcSEcCtD
Rivaroxaban—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.000674	0.00262	CcSEcCtD
Rivaroxaban—Malaise—Dactinomycin—uterine cancer	0.000674	0.00262	CcSEcCtD
Rivaroxaban—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.000669	0.0026	CcSEcCtD
Rivaroxaban—Blood urea increased—Epirubicin—uterine cancer	0.000655	0.00254	CcSEcCtD
Rivaroxaban—Hepatobiliary disease—Etoposide—uterine cancer	0.000655	0.00254	CcSEcCtD
Rivaroxaban—Agranulocytosis—Etoposide—uterine cancer	0.000646	0.00251	CcSEcCtD
Rivaroxaban—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	0.000645	0.0025	CcSEcCtD
Rivaroxaban—ABCB1—female gonad—uterine cancer	0.000644	0.00712	CbGeAlD
Rivaroxaban—ABCB1—vagina—uterine cancer	0.00064	0.00708	CbGeAlD
Rivaroxaban—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.00064	0.00248	CcSEcCtD
Rivaroxaban—Hypersensitivity—Progesterone—uterine cancer	0.000636	0.00247	CcSEcCtD
Rivaroxaban—Discomfort—Dactinomycin—uterine cancer	0.000629	0.00244	CcSEcCtD
Rivaroxaban—Ecchymosis—Epirubicin—uterine cancer	0.000627	0.00243	CcSEcCtD
Rivaroxaban—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.000621	0.00241	CcSEcCtD
Rivaroxaban—Asthenia—Progesterone—uterine cancer	0.000619	0.0024	CcSEcCtD
Rivaroxaban—CYP2J2—Arachidonic acid metabolism—AKR1C3—uterine cancer	0.000619	0.0456	CbGpPWpGaD
Rivaroxaban—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.000618	0.0024	CcSEcCtD
Rivaroxaban—Urinary tract disorder—Etoposide—uterine cancer	0.000614	0.00238	CcSEcCtD
Rivaroxaban—Pruritus—Progesterone—uterine cancer	0.000611	0.00237	CcSEcCtD
Rivaroxaban—Oedema—Dactinomycin—uterine cancer	0.00061	0.00237	CcSEcCtD
Rivaroxaban—Urethral disorder—Etoposide—uterine cancer	0.000609	0.00236	CcSEcCtD
Rivaroxaban—Infection—Dactinomycin—uterine cancer	0.000606	0.00235	CcSEcCtD
Rivaroxaban—Blood urea increased—Doxorubicin—uterine cancer	0.000606	0.00235	CcSEcCtD
Rivaroxaban—Diarrhoea—Progesterone—uterine cancer	0.000591	0.00229	CcSEcCtD
Rivaroxaban—Erythema multiforme—Etoposide—uterine cancer	0.000588	0.00228	CcSEcCtD
Rivaroxaban—Eye disorder—Etoposide—uterine cancer	0.000581	0.00225	CcSEcCtD
Rivaroxaban—Ecchymosis—Doxorubicin—uterine cancer	0.00058	0.00225	CcSEcCtD
Rivaroxaban—Cardiac disorder—Etoposide—uterine cancer	0.000577	0.00224	CcSEcCtD
Rivaroxaban—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.000576	0.00224	CcSEcCtD
Rivaroxaban—Hepatic function abnormal—Epirubicin—uterine cancer	0.000576	0.00224	CcSEcCtD
Rivaroxaban—Dizziness—Progesterone—uterine cancer	0.000571	0.00222	CcSEcCtD
Rivaroxaban—CYP2J2—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.000566	0.0418	CbGpPWpGaD
Rivaroxaban—Angiopathy—Etoposide—uterine cancer	0.000564	0.00219	CcSEcCtD
Rivaroxaban—Immune system disorder—Etoposide—uterine cancer	0.000561	0.00218	CcSEcCtD
Rivaroxaban—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000561	0.00218	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Etoposide—uterine cancer	0.00056	0.00217	CcSEcCtD
Rivaroxaban—CYP2J2—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.000559	0.0412	CbGpPWpGaD
Rivaroxaban—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000553	0.00215	CcSEcCtD
Rivaroxaban—Vomiting—Progesterone—uterine cancer	0.000549	0.00213	CcSEcCtD
Rivaroxaban—Renal failure acute—Epirubicin—uterine cancer	0.000546	0.00212	CcSEcCtD
Rivaroxaban—Rash—Progesterone—uterine cancer	0.000544	0.00211	CcSEcCtD
Rivaroxaban—Dermatitis—Progesterone—uterine cancer	0.000544	0.00211	CcSEcCtD
Rivaroxaban—Headache—Progesterone—uterine cancer	0.000541	0.0021	CcSEcCtD
Rivaroxaban—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000535	0.00208	CcSEcCtD
Rivaroxaban—Hepatic function abnormal—Doxorubicin—uterine cancer	0.000533	0.00207	CcSEcCtD
Rivaroxaban—Dermatitis bullous—Epirubicin—uterine cancer	0.000527	0.00204	CcSEcCtD
Rivaroxaban—Fatigue—Dactinomycin—uterine cancer	0.000526	0.00204	CcSEcCtD
Rivaroxaban—Back pain—Etoposide—uterine cancer	0.000523	0.00203	CcSEcCtD
Rivaroxaban—Pain—Dactinomycin—uterine cancer	0.000522	0.00202	CcSEcCtD
Rivaroxaban—Muscle spasms—Etoposide—uterine cancer	0.00052	0.00202	CcSEcCtD
Rivaroxaban—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000517	0.00201	CcSEcCtD
Rivaroxaban—CYP2J2—Tryptophan metabolism—CYP19A1—uterine cancer	0.000515	0.038	CbGpPWpGaD
Rivaroxaban—Nausea—Progesterone—uterine cancer	0.000513	0.00199	CcSEcCtD
Rivaroxaban—Renal failure acute—Doxorubicin—uterine cancer	0.000505	0.00196	CcSEcCtD
Rivaroxaban—Pain in extremity—Epirubicin—uterine cancer	0.000504	0.00195	CcSEcCtD
Rivaroxaban—Gastrointestinal haemorrhage—Epirubicin—uterine cancer	0.000504	0.00195	CcSEcCtD
Rivaroxaban—Osteoarthritis—Epirubicin—uterine cancer	0.000504	0.00195	CcSEcCtD
Rivaroxaban—Feeling abnormal—Dactinomycin—uterine cancer	0.000503	0.00195	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Etoposide—uterine cancer	0.000502	0.00195	CcSEcCtD
Rivaroxaban—Anaemia—Etoposide—uterine cancer	0.0005	0.00194	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000499	0.00194	CcSEcCtD
Rivaroxaban—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000497	0.00193	CcSEcCtD
Rivaroxaban—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000493	0.00191	CcSEcCtD
Rivaroxaban—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000493	0.00191	CcSEcCtD
Rivaroxaban—Headache—Medroxyprogesterone Acetate—uterine cancer	0.00049	0.0019	CcSEcCtD
Rivaroxaban—Malaise—Etoposide—uterine cancer	0.000488	0.00189	CcSEcCtD
Rivaroxaban—Dermatitis bullous—Doxorubicin—uterine cancer	0.000488	0.00189	CcSEcCtD
Rivaroxaban—Abdominal pain—Dactinomycin—uterine cancer	0.000482	0.00187	CcSEcCtD
Rivaroxaban—Loss of consciousness—Etoposide—uterine cancer	0.000476	0.00185	CcSEcCtD
Rivaroxaban—Blood creatinine increased—Epirubicin—uterine cancer	0.000472	0.00183	CcSEcCtD
Rivaroxaban—Pain in extremity—Doxorubicin—uterine cancer	0.000466	0.00181	CcSEcCtD
Rivaroxaban—Osteoarthritis—Doxorubicin—uterine cancer	0.000466	0.00181	CcSEcCtD
Rivaroxaban—Gastrointestinal haemorrhage—Doxorubicin—uterine cancer	0.000466	0.00181	CcSEcCtD
Rivaroxaban—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000465	0.0018	CcSEcCtD
Rivaroxaban—Chest pain—Etoposide—uterine cancer	0.000461	0.00179	CcSEcCtD
Rivaroxaban—Abdominal pain upper—Epirubicin—uterine cancer	0.00046	0.00178	CcSEcCtD
Rivaroxaban—CYP2J2—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.000459	0.0339	CbGpPWpGaD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000458	0.00178	CcSEcCtD
Rivaroxaban—Discomfort—Etoposide—uterine cancer	0.000455	0.00177	CcSEcCtD
Rivaroxaban—Hypersensitivity—Dactinomycin—uterine cancer	0.00045	0.00174	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Etoposide—uterine cancer	0.000442	0.00171	CcSEcCtD
Rivaroxaban—Infection—Etoposide—uterine cancer	0.000439	0.0017	CcSEcCtD
Rivaroxaban—Asthenia—Dactinomycin—uterine cancer	0.000438	0.0017	CcSEcCtD
Rivaroxaban—Blood creatinine increased—Doxorubicin—uterine cancer	0.000437	0.00169	CcSEcCtD
Rivaroxaban—CYP2J2—Metapathway biotransformation—AKR1B10—uterine cancer	0.000432	0.0319	CbGpPWpGaD
Rivaroxaban—Tachycardia—Etoposide—uterine cancer	0.000431	0.00167	CcSEcCtD
Rivaroxaban—Skin disorder—Etoposide—uterine cancer	0.000429	0.00166	CcSEcCtD
Rivaroxaban—Abdominal pain upper—Doxorubicin—uterine cancer	0.000426	0.00165	CcSEcCtD
Rivaroxaban—CYP3A4—Benzo(a)pyrene metabolism—AKR1C1—uterine cancer	0.000425	0.0313	CbGpPWpGaD
Rivaroxaban—Angina pectoris—Epirubicin—uterine cancer	0.000424	0.00165	CcSEcCtD
Rivaroxaban—Diarrhoea—Dactinomycin—uterine cancer	0.000418	0.00162	CcSEcCtD
Rivaroxaban—CYP2J2—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	0.000417	0.0307	CbGpPWpGaD
Rivaroxaban—ABCB1—lymph node—uterine cancer	0.000414	0.00458	CbGeAlD
Rivaroxaban—Hypotension—Etoposide—uterine cancer	0.000413	0.0016	CcSEcCtD
Rivaroxaban—CYP2J2—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.000411	0.0303	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metapathway biotransformation—AKR1B1—uterine cancer	0.000402	0.0296	CbGpPWpGaD
Rivaroxaban—Dyspnoea—Etoposide—uterine cancer	0.000394	0.00153	CcSEcCtD
Rivaroxaban—Angina pectoris—Doxorubicin—uterine cancer	0.000392	0.00152	CcSEcCtD
Rivaroxaban—Infestation NOS—Epirubicin—uterine cancer	0.000388	0.00151	CcSEcCtD
Rivaroxaban—Infestation—Epirubicin—uterine cancer	0.000388	0.00151	CcSEcCtD
Rivaroxaban—Vomiting—Dactinomycin—uterine cancer	0.000388	0.00151	CcSEcCtD
Rivaroxaban—Stevens-Johnson syndrome—Epirubicin—uterine cancer	0.000385	0.00149	CcSEcCtD
Rivaroxaban—Rash—Dactinomycin—uterine cancer	0.000385	0.00149	CcSEcCtD
Rivaroxaban—Renal failure—Epirubicin—uterine cancer	0.000382	0.00148	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Etoposide—uterine cancer	0.000381	0.00148	CcSEcCtD
Rivaroxaban—Fatigue—Etoposide—uterine cancer	0.000381	0.00148	CcSEcCtD
Rivaroxaban—Jaundice—Epirubicin—uterine cancer	0.000378	0.00147	CcSEcCtD
Rivaroxaban—Constipation—Etoposide—uterine cancer	0.000378	0.00147	CcSEcCtD
Rivaroxaban—Pain—Etoposide—uterine cancer	0.000378	0.00147	CcSEcCtD
Rivaroxaban—Urinary tract infection—Epirubicin—uterine cancer	0.000377	0.00146	CcSEcCtD
Rivaroxaban—Haematuria—Epirubicin—uterine cancer	0.00037	0.00144	CcSEcCtD
Rivaroxaban—Hepatobiliary disease—Epirubicin—uterine cancer	0.000367	0.00142	CcSEcCtD
Rivaroxaban—Epistaxis—Epirubicin—uterine cancer	0.000366	0.00142	CcSEcCtD
Rivaroxaban—Sinusitis—Epirubicin—uterine cancer	0.000364	0.00141	CcSEcCtD
Rivaroxaban—Feeling abnormal—Etoposide—uterine cancer	0.000364	0.00141	CcSEcCtD
Rivaroxaban—Nausea—Dactinomycin—uterine cancer	0.000362	0.00141	CcSEcCtD
Rivaroxaban—Agranulocytosis—Epirubicin—uterine cancer	0.000362	0.00141	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Etoposide—uterine cancer	0.000361	0.0014	CcSEcCtD
Rivaroxaban—Infestation NOS—Doxorubicin—uterine cancer	0.000359	0.00139	CcSEcCtD
Rivaroxaban—Infestation—Doxorubicin—uterine cancer	0.000359	0.00139	CcSEcCtD
Rivaroxaban—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	0.000356	0.00138	CcSEcCtD
Rivaroxaban—Renal failure—Doxorubicin—uterine cancer	0.000353	0.00137	CcSEcCtD
Rivaroxaban—Urticaria—Etoposide—uterine cancer	0.000351	0.00136	CcSEcCtD
Rivaroxaban—Haemoglobin—Epirubicin—uterine cancer	0.00035	0.00136	CcSEcCtD
Rivaroxaban—Jaundice—Doxorubicin—uterine cancer	0.00035	0.00136	CcSEcCtD
Rivaroxaban—Abdominal pain—Etoposide—uterine cancer	0.000349	0.00135	CcSEcCtD
Rivaroxaban—Urinary tract infection—Doxorubicin—uterine cancer	0.000349	0.00135	CcSEcCtD
Rivaroxaban—Hepatitis—Epirubicin—uterine cancer	0.000348	0.00135	CcSEcCtD
Rivaroxaban—Haemorrhage—Epirubicin—uterine cancer	0.000348	0.00135	CcSEcCtD
Rivaroxaban—Urinary tract disorder—Epirubicin—uterine cancer	0.000344	0.00134	CcSEcCtD
Rivaroxaban—Haematuria—Doxorubicin—uterine cancer	0.000342	0.00133	CcSEcCtD
Rivaroxaban—Connective tissue disorder—Epirubicin—uterine cancer	0.000342	0.00133	CcSEcCtD
Rivaroxaban—Urethral disorder—Epirubicin—uterine cancer	0.000342	0.00133	CcSEcCtD
Rivaroxaban—Hepatobiliary disease—Doxorubicin—uterine cancer	0.00034	0.00132	CcSEcCtD
Rivaroxaban—Epistaxis—Doxorubicin—uterine cancer	0.000339	0.00131	CcSEcCtD
Rivaroxaban—CYP2J2—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.000338	0.0249	CbGpPWpGaD
Rivaroxaban—Sinusitis—Doxorubicin—uterine cancer	0.000337	0.00131	CcSEcCtD
Rivaroxaban—Agranulocytosis—Doxorubicin—uterine cancer	0.000335	0.0013	CcSEcCtD
Rivaroxaban—Erythema multiforme—Epirubicin—uterine cancer	0.000329	0.00128	CcSEcCtD
Rivaroxaban—CYP3A4—Benzo(a)pyrene metabolism—AKR1C3—uterine cancer	0.000327	0.0241	CbGpPWpGaD
Rivaroxaban—Eye disorder—Epirubicin—uterine cancer	0.000326	0.00126	CcSEcCtD
Rivaroxaban—Hypersensitivity—Etoposide—uterine cancer	0.000325	0.00126	CcSEcCtD
Rivaroxaban—Haemoglobin—Doxorubicin—uterine cancer	0.000324	0.00126	CcSEcCtD
Rivaroxaban—Cardiac disorder—Epirubicin—uterine cancer	0.000323	0.00125	CcSEcCtD
Rivaroxaban—Haemorrhage—Doxorubicin—uterine cancer	0.000322	0.00125	CcSEcCtD
Rivaroxaban—Hepatitis—Doxorubicin—uterine cancer	0.000322	0.00125	CcSEcCtD
Rivaroxaban—Urinary tract disorder—Doxorubicin—uterine cancer	0.000318	0.00124	CcSEcCtD
Rivaroxaban—Asthenia—Etoposide—uterine cancer	0.000317	0.00123	CcSEcCtD
Rivaroxaban—Connective tissue disorder—Doxorubicin—uterine cancer	0.000317	0.00123	CcSEcCtD
Rivaroxaban—Angiopathy—Epirubicin—uterine cancer	0.000316	0.00123	CcSEcCtD
Rivaroxaban—Urethral disorder—Doxorubicin—uterine cancer	0.000316	0.00123	CcSEcCtD
Rivaroxaban—Immune system disorder—Epirubicin—uterine cancer	0.000315	0.00122	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Epirubicin—uterine cancer	0.000314	0.00122	CcSEcCtD
Rivaroxaban—Pruritus—Etoposide—uterine cancer	0.000312	0.00121	CcSEcCtD
Rivaroxaban—ABCB1—ABC-family proteins mediated transport—ABCC9—uterine cancer	0.00031	0.0228	CbGpPWpGaD
Rivaroxaban—Erythema multiforme—Doxorubicin—uterine cancer	0.000305	0.00118	CcSEcCtD
Rivaroxaban—Diarrhoea—Etoposide—uterine cancer	0.000302	0.00117	CcSEcCtD
Rivaroxaban—Eye disorder—Doxorubicin—uterine cancer	0.000301	0.00117	CcSEcCtD
Rivaroxaban—Cardiac disorder—Doxorubicin—uterine cancer	0.000299	0.00116	CcSEcCtD
Rivaroxaban—CYP2J2—Metapathway biotransformation—AKR1C1—uterine cancer	0.000295	0.0218	CbGpPWpGaD
Rivaroxaban—Back pain—Epirubicin—uterine cancer	0.000293	0.00114	CcSEcCtD
Rivaroxaban—Angiopathy—Doxorubicin—uterine cancer	0.000293	0.00113	CcSEcCtD
Rivaroxaban—Dizziness—Etoposide—uterine cancer	0.000292	0.00113	CcSEcCtD
Rivaroxaban—Muscle spasms—Epirubicin—uterine cancer	0.000292	0.00113	CcSEcCtD
Rivaroxaban—Immune system disorder—Doxorubicin—uterine cancer	0.000291	0.00113	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Doxorubicin—uterine cancer	0.000291	0.00113	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Epirubicin—uterine cancer	0.000281	0.00109	CcSEcCtD
Rivaroxaban—Vomiting—Etoposide—uterine cancer	0.000281	0.00109	CcSEcCtD
Rivaroxaban—Anaemia—Epirubicin—uterine cancer	0.00028	0.00109	CcSEcCtD
Rivaroxaban—Rash—Etoposide—uterine cancer	0.000278	0.00108	CcSEcCtD
Rivaroxaban—Dermatitis—Etoposide—uterine cancer	0.000278	0.00108	CcSEcCtD
Rivaroxaban—Headache—Etoposide—uterine cancer	0.000277	0.00107	CcSEcCtD
Rivaroxaban—Malaise—Epirubicin—uterine cancer	0.000274	0.00106	CcSEcCtD
Rivaroxaban—Syncope—Epirubicin—uterine cancer	0.000272	0.00106	CcSEcCtD
Rivaroxaban—Back pain—Doxorubicin—uterine cancer	0.000271	0.00105	CcSEcCtD
Rivaroxaban—Muscle spasms—Doxorubicin—uterine cancer	0.00027	0.00105	CcSEcCtD
Rivaroxaban—Loss of consciousness—Epirubicin—uterine cancer	0.000267	0.00103	CcSEcCtD
Rivaroxaban—Nausea—Etoposide—uterine cancer	0.000262	0.00102	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Doxorubicin—uterine cancer	0.00026	0.00101	CcSEcCtD
Rivaroxaban—Anaemia—Doxorubicin—uterine cancer	0.000259	0.00101	CcSEcCtD
Rivaroxaban—CYP2J2—Metapathway biotransformation—GPX3—uterine cancer	0.000259	0.0191	CbGpPWpGaD
Rivaroxaban—Chest pain—Epirubicin—uterine cancer	0.000258	0.001	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000256	0.000995	CcSEcCtD
Rivaroxaban—Discomfort—Epirubicin—uterine cancer	0.000255	0.00099	CcSEcCtD
Rivaroxaban—Malaise—Doxorubicin—uterine cancer	0.000253	0.000982	CcSEcCtD
Rivaroxaban—Dry mouth—Epirubicin—uterine cancer	0.000253	0.00098	CcSEcCtD
Rivaroxaban—Syncope—Doxorubicin—uterine cancer	0.000252	0.000977	CcSEcCtD
Rivaroxaban—F10—Metabolism of proteins—TSPYL2—uterine cancer	0.000251	0.0185	CbGpPWpGaD
Rivaroxaban—Anaphylactic shock—Epirubicin—uterine cancer	0.000248	0.000961	CcSEcCtD
Rivaroxaban—Oedema—Epirubicin—uterine cancer	0.000248	0.000961	CcSEcCtD
Rivaroxaban—Loss of consciousness—Doxorubicin—uterine cancer	0.000247	0.000957	CcSEcCtD
Rivaroxaban—Infection—Epirubicin—uterine cancer	0.000246	0.000954	CcSEcCtD
Rivaroxaban—CYP2J2—Biological oxidations—CYP11A1—uterine cancer	0.000244	0.018	CbGpPWpGaD
Rivaroxaban—Shock—Epirubicin—uterine cancer	0.000244	0.000945	CcSEcCtD
Rivaroxaban—Nervous system disorder—Epirubicin—uterine cancer	0.000243	0.000942	CcSEcCtD
Rivaroxaban—Tachycardia—Epirubicin—uterine cancer	0.000242	0.000937	CcSEcCtD
Rivaroxaban—CYP2J2—Metapathway biotransformation—CYP11A1—uterine cancer	0.000241	0.0177	CbGpPWpGaD
Rivaroxaban—Skin disorder—Epirubicin—uterine cancer	0.00024	0.000933	CcSEcCtD
Rivaroxaban—Chest pain—Doxorubicin—uterine cancer	0.000239	0.000927	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000237	0.000921	CcSEcCtD
Rivaroxaban—Discomfort—Doxorubicin—uterine cancer	0.000236	0.000916	CcSEcCtD
Rivaroxaban—Dry mouth—Doxorubicin—uterine cancer	0.000234	0.000907	CcSEcCtD
Rivaroxaban—Hypotension—Epirubicin—uterine cancer	0.000231	0.000898	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Doxorubicin—uterine cancer	0.000229	0.000889	CcSEcCtD
Rivaroxaban—Oedema—Doxorubicin—uterine cancer	0.000229	0.000889	CcSEcCtD
Rivaroxaban—Infection—Doxorubicin—uterine cancer	0.000228	0.000883	CcSEcCtD
Rivaroxaban—CYP2J2—Metapathway biotransformation—AKR1C3—uterine cancer	0.000227	0.0168	CbGpPWpGaD
Rivaroxaban—Shock—Doxorubicin—uterine cancer	0.000225	0.000874	CcSEcCtD
Rivaroxaban—Nervous system disorder—Doxorubicin—uterine cancer	0.000225	0.000872	CcSEcCtD
Rivaroxaban—Tachycardia—Doxorubicin—uterine cancer	0.000224	0.000867	CcSEcCtD
Rivaroxaban—Skin disorder—Doxorubicin—uterine cancer	0.000222	0.000863	CcSEcCtD
Rivaroxaban—Dyspnoea—Epirubicin—uterine cancer	0.000221	0.000856	CcSEcCtD
Rivaroxaban—Dyspepsia—Epirubicin—uterine cancer	0.000218	0.000846	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.000217	0.016	CbGpPWpGaD
Rivaroxaban—Hypotension—Doxorubicin—uterine cancer	0.000214	0.00083	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000214	0.000829	CcSEcCtD
Rivaroxaban—Fatigue—Epirubicin—uterine cancer	0.000213	0.000828	CcSEcCtD
Rivaroxaban—Pain—Epirubicin—uterine cancer	0.000212	0.000821	CcSEcCtD
Rivaroxaban—Constipation—Epirubicin—uterine cancer	0.000212	0.000821	CcSEcCtD
Rivaroxaban—Dyspnoea—Doxorubicin—uterine cancer	0.000204	0.000792	CcSEcCtD
Rivaroxaban—Feeling abnormal—Epirubicin—uterine cancer	0.000204	0.000792	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Epirubicin—uterine cancer	0.000202	0.000785	CcSEcCtD
Rivaroxaban—Dyspepsia—Doxorubicin—uterine cancer	0.000202	0.000782	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000198	0.000767	CcSEcCtD
Rivaroxaban—Fatigue—Doxorubicin—uterine cancer	0.000197	0.000766	CcSEcCtD
Rivaroxaban—Urticaria—Epirubicin—uterine cancer	0.000197	0.000763	CcSEcCtD
Rivaroxaban—Pain—Doxorubicin—uterine cancer	0.000196	0.00076	CcSEcCtD
Rivaroxaban—Constipation—Doxorubicin—uterine cancer	0.000196	0.00076	CcSEcCtD
Rivaroxaban—Abdominal pain—Epirubicin—uterine cancer	0.000196	0.000759	CcSEcCtD
Rivaroxaban—Feeling abnormal—Doxorubicin—uterine cancer	0.000189	0.000732	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000187	0.000727	CcSEcCtD
Rivaroxaban—Hypersensitivity—Epirubicin—uterine cancer	0.000182	0.000708	CcSEcCtD
Rivaroxaban—Urticaria—Doxorubicin—uterine cancer	0.000182	0.000706	CcSEcCtD
Rivaroxaban—Abdominal pain—Doxorubicin—uterine cancer	0.000181	0.000703	CcSEcCtD
Rivaroxaban—CYP2J2—Biological oxidations—CYP19A1—uterine cancer	0.000179	0.0132	CbGpPWpGaD
Rivaroxaban—Asthenia—Epirubicin—uterine cancer	0.000178	0.000689	CcSEcCtD
Rivaroxaban—CYP2J2—Metapathway biotransformation—CYP19A1—uterine cancer	0.000177	0.0131	CbGpPWpGaD
Rivaroxaban—Pruritus—Epirubicin—uterine cancer	0.000175	0.00068	CcSEcCtD
Rivaroxaban—Diarrhoea—Epirubicin—uterine cancer	0.000169	0.000657	CcSEcCtD
Rivaroxaban—Hypersensitivity—Doxorubicin—uterine cancer	0.000169	0.000655	CcSEcCtD
Rivaroxaban—Asthenia—Doxorubicin—uterine cancer	0.000164	0.000638	CcSEcCtD
Rivaroxaban—Dizziness—Epirubicin—uterine cancer	0.000164	0.000635	CcSEcCtD
Rivaroxaban—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.000163	0.012	CbGpPWpGaD
Rivaroxaban—Pruritus—Doxorubicin—uterine cancer	0.000162	0.000629	CcSEcCtD
Rivaroxaban—CYP3A5—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.000161	0.0119	CbGpPWpGaD
Rivaroxaban—Vomiting—Epirubicin—uterine cancer	0.000157	0.000611	CcSEcCtD
Rivaroxaban—Diarrhoea—Doxorubicin—uterine cancer	0.000157	0.000608	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—STAR—uterine cancer	0.000157	0.0115	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	0.000157	0.0115	CbGpPWpGaD
Rivaroxaban—Rash—Epirubicin—uterine cancer	0.000156	0.000606	CcSEcCtD
Rivaroxaban—Dermatitis—Epirubicin—uterine cancer	0.000156	0.000605	CcSEcCtD
Rivaroxaban—Headache—Epirubicin—uterine cancer	0.000155	0.000602	CcSEcCtD
Rivaroxaban—Dizziness—Doxorubicin—uterine cancer	0.000151	0.000588	CcSEcCtD
Rivaroxaban—Nausea—Epirubicin—uterine cancer	0.000147	0.000571	CcSEcCtD
Rivaroxaban—Vomiting—Doxorubicin—uterine cancer	0.000146	0.000565	CcSEcCtD
Rivaroxaban—Rash—Doxorubicin—uterine cancer	0.000144	0.00056	CcSEcCtD
Rivaroxaban—Dermatitis—Doxorubicin—uterine cancer	0.000144	0.00056	CcSEcCtD
Rivaroxaban—Headache—Doxorubicin—uterine cancer	0.000143	0.000557	CcSEcCtD
Rivaroxaban—Nausea—Doxorubicin—uterine cancer	0.000136	0.000528	CcSEcCtD
Rivaroxaban—CYP3A5—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.000132	0.00976	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—AKR1B10—uterine cancer	0.000125	0.00919	CbGpPWpGaD
Rivaroxaban—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	0.00012	0.00886	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—MAP3K4—uterine cancer	0.000119	0.00877	CbGpPWpGaD
Rivaroxaban—CYP3A5—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.000119	0.00874	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—AKR1B1—uterine cancer	0.000116	0.00854	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	0.000115	0.00847	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—INHBA—uterine cancer	0.000112	0.00826	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—MME—uterine cancer	0.000105	0.00777	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—IRF1—uterine cancer	9.82e-05	0.00724	CbGpPWpGaD
Rivaroxaban—CYP3A5—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	9.74e-05	0.00718	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—SRD5A2—uterine cancer	9.64e-05	0.00711	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—NDUFB11—uterine cancer	9.64e-05	0.00711	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	9.37e-05	0.00691	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	8.85e-05	0.00652	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—AKR1C1—uterine cancer	8.51e-05	0.00627	CbGpPWpGaD
Rivaroxaban—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	7.59e-05	0.0056	CbGpPWpGaD
Rivaroxaban—CYP3A4—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	7.49e-05	0.00552	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—GPX3—uterine cancer	7.47e-05	0.00551	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—CYP11A1—uterine cancer	7.03e-05	0.00518	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—AKR1B1—uterine cancer	6.97e-05	0.00514	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—STAR—uterine cancer	6.97e-05	0.00514	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—CYP11A1—uterine cancer	6.93e-05	0.00511	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—FBXW7—uterine cancer	6.92e-05	0.0051	CbGpPWpGaD
Rivaroxaban—CYP3A4—Tryptophan metabolism—CYP19A1—uterine cancer	6.91e-05	0.00509	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	6.89e-05	0.00508	CbGpPWpGaD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—SMAD3—uterine cancer	6.87e-05	0.00507	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—INHBA—uterine cancer	6.65e-05	0.0049	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—AKR1C3—uterine cancer	6.55e-05	0.00483	CbGpPWpGaD
Rivaroxaban—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	6.15e-05	0.00454	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—AKR1B10—uterine cancer	5.79e-05	0.00427	CbGpPWpGaD
Rivaroxaban—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	5.58e-05	0.00412	CbGpPWpGaD
Rivaroxaban—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	5.51e-05	0.00406	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—POLD1—uterine cancer	5.47e-05	0.00403	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—AKR1B1—uterine cancer	5.39e-05	0.00397	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—CYP19A1—uterine cancer	5.17e-05	0.00381	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—AKR1C1—uterine cancer	5.12e-05	0.00377	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—CYP19A1—uterine cancer	5.1e-05	0.00376	CbGpPWpGaD
Rivaroxaban—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—uterine cancer	4.84e-05	0.00357	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—RRM2—uterine cancer	4.56e-05	0.00336	CbGpPWpGaD
Rivaroxaban—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	4.53e-05	0.00334	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—DCN—uterine cancer	4.43e-05	0.00326	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	4.26e-05	0.00314	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—CYP11A1—uterine cancer	4.17e-05	0.00308	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—AKR1C1—uterine cancer	3.95e-05	0.00292	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	3.95e-05	0.00291	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—AKR1C3—uterine cancer	3.94e-05	0.0029	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	3.59e-05	0.00265	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—CCL2—uterine cancer	3.56e-05	0.00262	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	3.47e-05	0.00256	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—CXCL8—uterine cancer	3.38e-05	0.00249	CbGpPWpGaD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—EP300—uterine cancer	3.35e-05	0.00247	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	3.27e-05	0.00241	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—ABCC9—uterine cancer	3.24e-05	0.00239	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	3.22e-05	0.00238	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	3.22e-05	0.00237	CbGpPWpGaD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—VEGFA—uterine cancer	3.17e-05	0.00234	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—CYP19A1—uterine cancer	3.07e-05	0.00226	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—STK11—uterine cancer	3.07e-05	0.00226	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—EP300—uterine cancer	3.07e-05	0.00226	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	3.04e-05	0.00224	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—VEGFA—uterine cancer	2.9e-05	0.00214	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	2.88e-05	0.00212	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—NRAS—uterine cancer	2.87e-05	0.00211	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—CXCL8—uterine cancer	2.81e-05	0.00207	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—SRD5A2—uterine cancer	2.78e-05	0.00205	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—NDUFB11—uterine cancer	2.78e-05	0.00205	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.75e-05	0.00203	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—VEGFA—uterine cancer	2.75e-05	0.00202	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—CTNNB1—uterine cancer	2.59e-05	0.00191	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—KRAS—uterine cancer	2.47e-05	0.00182	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	2.4e-05	0.00177	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	2.4e-05	0.00177	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	2.37e-05	0.00175	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—MTHFR—uterine cancer	2.31e-05	0.0017	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—PIK3CA—uterine cancer	2.27e-05	0.00167	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—TP53—uterine cancer	2.19e-05	0.00162	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—HRAS—uterine cancer	2.1e-05	0.00155	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—NDUFB11—uterine cancer	2.1e-05	0.00155	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—SRD5A2—uterine cancer	2.1e-05	0.00155	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.03e-05	0.0015	CbGpPWpGaD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—AKT1—uterine cancer	2.02e-05	0.00149	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—STAR—uterine cancer	2.01e-05	0.00148	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—AKR1B1—uterine cancer	2.01e-05	0.00148	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—AKT1—uterine cancer	1.85e-05	0.00137	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	1.76e-05	0.0013	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	1.63e-05	0.0012	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—POLD1—uterine cancer	1.58e-05	0.00116	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	1.54e-05	0.00114	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—STAR—uterine cancer	1.52e-05	0.00112	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—AKR1B1—uterine cancer	1.52e-05	0.00112	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	1.5e-05	0.00111	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—AKR1C1—uterine cancer	1.47e-05	0.00109	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	1.43e-05	0.00106	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	1.36e-05	0.000999	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—RRM2—uterine cancer	1.31e-05	0.000969	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—SRD5A2—uterine cancer	1.29e-05	0.000953	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—NDUFB11—uterine cancer	1.29e-05	0.000953	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PTEN—uterine cancer	1.28e-05	0.000946	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—DCN—uterine cancer	1.28e-05	0.000941	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—EP300—uterine cancer	1.22e-05	0.000902	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CYP11A1—uterine cancer	1.2e-05	0.000886	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—POLD1—uterine cancer	1.19e-05	0.000877	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	1.15e-05	0.00085	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—AKR1C3—uterine cancer	1.14e-05	0.000837	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—AKR1C1—uterine cancer	1.11e-05	0.000821	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	1.06e-05	0.00078	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	1.02e-05	0.000755	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—RRM2—uterine cancer	9.92e-06	0.000731	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—DCN—uterine cancer	9.63e-06	0.00071	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—AKR1B1—uterine cancer	9.34e-06	0.000689	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—STAR—uterine cancer	9.34e-06	0.000689	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CYP11A1—uterine cancer	9.07e-06	0.000669	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PIK3CA—uterine cancer	9.05e-06	0.000667	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—STK11—uterine cancer	8.84e-06	0.000652	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CYP19A1—uterine cancer	8.84e-06	0.000652	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	8.65e-06	0.000638	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—AKR1C3—uterine cancer	8.57e-06	0.000632	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—AKT1—uterine cancer	7.39e-06	0.000545	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—POLD1—uterine cancer	7.33e-06	0.000541	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—AKR1C1—uterine cancer	6.86e-06	0.000506	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—STK11—uterine cancer	6.67e-06	0.000492	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CYP19A1—uterine cancer	6.67e-06	0.000492	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—MTHFR—uterine cancer	6.65e-06	0.00049	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—RRM2—uterine cancer	6.11e-06	0.000451	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—DCN—uterine cancer	5.93e-06	0.000437	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CYP11A1—uterine cancer	5.59e-06	0.000412	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—AKR1C3—uterine cancer	5.28e-06	0.000389	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—MTHFR—uterine cancer	5.02e-06	0.00037	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—STK11—uterine cancer	4.11e-06	0.000303	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CYP19A1—uterine cancer	4.11e-06	0.000303	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PTEN—uterine cancer	3.7e-06	0.000273	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—EP300—uterine cancer	3.53e-06	0.00026	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—MTHFR—uterine cancer	3.09e-06	0.000228	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PTEN—uterine cancer	2.79e-06	0.000206	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—EP300—uterine cancer	2.66e-06	0.000196	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PIK3CA—uterine cancer	2.61e-06	0.000192	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—AKT1—uterine cancer	2.13e-06	0.000157	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PIK3CA—uterine cancer	1.97e-06	0.000145	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PTEN—uterine cancer	1.72e-06	0.000127	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—EP300—uterine cancer	1.64e-06	0.000121	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—AKT1—uterine cancer	1.61e-06	0.000119	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PIK3CA—uterine cancer	1.21e-06	8.94e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—AKT1—uterine cancer	9.91e-07	7.31e-05	CbGpPWpGaD
